relacorilant (Lifyorli)

Indications

• treatment of adults with platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with 1-3 prior systemic treatment, at least one of which included bevacizumab.

Contraindications

• systemic glucocorticoid dependence (immunosupression after organ transplantation)
  • relacorilant antagonizes the effect of glucocorticoids
• pregnancy:
  • use contraception during treatment with relacorilant & for 1 week after last dose

Dosage

• 150 mg PO QD for 3 days, synchronized with infusion of nab-paclitaxel the day prior to, the day of & the day after infusion

* Nab-paclitaxel 80 mg/m2 IV infusion over 30-40 minutes on Day 1, Day 8, & Day 15 of a 28-day cycle

Adverse effects

• neutropenia
  • administration of granulocyte stimulating factor common
• adrenal insufficiency
• pancytopenia

Mechanism of action

• selective glucocorticoid receptor antagonist

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=73051463
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=155884885